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Murine gammaherpesvirus 68 (gHV68, MHV-68)-specific CD4 T cells control gHV68 infection by reducing the frequency of latently
infected cells and by inhibiting viral replication. We have previously demonstrated that CD4 T cells do not require CD8 T or B cells to control
gHV68 replication, demonstrating a helper-independent activity of CD4 T cells during gHV68 infection. The effector mechanism(s) required
for this helper-independent function of CD4 T cells and for the inhibition of the establishment of latency by CD4 T cells are not known. Since
IFNg has been previously shown to be important for control of acute, latent, and persistent gHV68 infection, we tested the hypothesis that
CD4 T cells require IFNg to limit gHV68 latency and replication. We utilized a previously described system in which T cell receptor (TCR)
transgenic T cells (DO.11.10) and a recombinant virus (gHV68.OVA) allow for evaluation of high numbers of virus-specific CD4 T cells
during both acute and latent infection. We show here that virus-specific CD4 T cells require IFNg for their anti-viral function in both acute
and latent gHV68 infection. We additionally show that an in vitro derived T helper type 1 (TH1) CD4 T cell clone, which produces IFNg,
inhibits gHV68 replication after adoptive transfer into RAG mice. Together, data presented here demonstrate that both CD4 T cell-mediated
helper-independent control of gHV68 replication and inhibition of the establishment of gHV68 latency require IFNg.
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To better understand g-herpesvirus pathogenesis and to
identify immune mechanisms that contribute to the main-
tenance of the host–virus equilibrium during chronic
infection, we and others have studied murine gHV68
(Christensen et al., 1999; Flan˜o et al., 2001; Kim et al.,
2002; McClellan et al., 2004; Sparks-Thissen et al., 2004;
Stevenson and Doherty, 1998; Stevenson et al., 1999;
Tibbetts et al., 2002, 2003; Tripp et al., 1997; Usherwood
et al., 2000). gHV68 infects inbred and outbred strains of
mice and establishes latency in B cells, macrophages, and0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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50112, USA.dendritic cells (Flan˜o et al., 2000, 2002, 2003; Sunil-
Chandra et al., 1992; Weck et al., 1999; Willer and Speck,
2003). Chronic gHV68 infection is associated with athero-
sclerosis, induction of tumors, and severe large vessel
arteritis in immunodeficient mice (Alber et al., 2000; Dal
Canto et al., 2000, 2001; Sunil- Chandra et al., 1994; Weck
et al., 1997). In wildtype mice, CD4 T cells are induced
during gHV68 infection and are critically important for the
control of gHV68 replication and latency (Christensen et al.,
1999; Flan˜o et al., 2001; McClellan et al., 2004; Sparks-
Thissen et al., 2004).
Much of what has been learned about the immune
response to gHV68 infection has come from evaluating
infection of different genetically modified mice which lack
various arms of the adaptive immune system. An alternative
approach that we have taken recently is to use a reductive
model system in which only one arm of the immune system05) 201 – 208
Rapid Communication202is evaluated in the context gHV68 infection. We have
previously evaluated infection with a recombinant virus
expressing ovalbumin (gHV68.OVA) in mice that express
TCR transgenic CD4 or CD8 T cells on either wildtype or
RAG/ genetic backgrounds; this system allows for an
evaluation of the function of each of these T cell subsets
during acute and latent infection (Braaten et al., 2005;
Sparks-Thissen et al., 2004).
In the case of CD4 T cell function, we previously
evaluated infection with gHV68.OVA in both DO.11.10/
BALB and OTII/BL6 mice, both of which express CD4 T
cells specific for the MHC Class II epitope of OVA (amino
acids 323–339, ISQAVHAAHAEINE) (Barnden et al.,
1998; Murphy et al., 1990; Sparks-Thissen et al., 2004).
We showed that CD4 Tcells demonstrate helper-independent
antiviral function, measured as the capacity to inhibit viral
replication, during gHV68 infection (Sparks-Thissen et al.,
2004). The most convincing data for this conclusion are from
experiments with mice that express the OVA CD4 transgenic
T cells on a RAG/ background. In these mice, the OVA-
specific CD4 T cells decreased gHV68.OVA replication and
modestly delayed death from infection (Sparks-Thissen et
al., 2004). In a related series of experiments we also
demonstrated that OVA-specific CD4 transgenic T cells
present at the initiation of infection in mice containing CD8
T and B cells are able to inhibit the establishment of latent
gHV68 infection (Sparks-Thissen et al., 2004). This latter
observation corroborated previously published studies dem-
onstrating that CD4 T cells play a key role in effective
vaccination against the establishment of gHV68 latency
(McClellan et al., 2004; Tibbetts et al., 2003b).
Several previous studies have demonstrated that control
of gHV68 infection requires IFNg. Mice lacking IFNg
(IFNg/) or the IFNg receptor (IFNgR/) have
increased persistent replication (defined as preformed
infectious virus present at a low level after clearance of
acute infection) for months after infection (Dal Canto et al.,
2000, 2001; Gangappa et al., 2002; Tibbetts et al., 2002;
Weck et al., 1997), and peritoneal cells taken from latently
infected animals reactivate infectious virus ex vivo more
efficiently than cells from wildtype mice. (Tibbetts et al.,
2002). IFNg/ and IFNgR/ mice also develop large
vessel arteritis after infection with gHV68 (Dal Canto et al.,
2000, 2001; Weck et al., 1997), which is caused by
persistent replication of virus in the smooth muscle cells
of the aortic media, an immunoprivileged site that requires
IFNg for virus clearance (Dal Canto et al., 2000, 2001;
Weck et al., 1997).
gHV68-specific CD4 T cells have been shown to
produce IFNg after antigen stimulation (Brooks et al.,
1999; Christensen and Doherty, 1999; Sarawar et al., 1996;
Usherwood, 2002). However, it is not known if effective
CD4 T cell responses to gHV68 require IFNg. A study by
Christensen et al. demonstrated that B cell deficient mice
depleted of both CD8 T cells and IFNg succumbed to
infection and had increased gHV68 titers compared to micedepleted only of CD8 T cells (Christensen et al., 1999).
These data indicate that IFNg derived from either CD4 T
cells or other cells (e.g., NK cells, but not CD8 T or B cells)
is required for CD4 T cell-dependent control of gHV68
infection. Given these data, we directly tested whether IFNg
is necessary for both CD4 T cell-mediated inhibition of the
establishment of latency and the helper-independent func-
tion in limiting gHV68.OVA replication. We found that
IFNg is necessary for CD4 T cell-mediated control of latent
and productive gHV68 infection. We also show that a stable
TH1 differentiated IFNg expressing DO.11.10 T cell clone
is sufficient for control of acute gHV68.OVA replication in
RAG/ mice.Results and discussion
Inhibition of the establishment of cHV68 latency by CD4
T cells requires IFNc
We first tested whether virus-specific CD4 T cells require
IFNg for control of gHV68 latency by depleting IFNg in
vivo with the monoclonal antibody H22 during infection
(Bancroft et al., 1987; Schreiber et al., 1985). DO.11.10
mice received injections of H22 [or isotype control
(Mandik-Nayak et al., 2001)] starting the day before
intraperitoneal infection with 100 pfu of either gHV68.OVA
or the control virus gHV68.LacZ (Sparks-Thissen et al.,
2004; Van Dyk et al., 2000). Sixteen days after infection,
peritoneal cells were harvested and analyzed for reactivation
from latency and for the frequency of cells carrying latent
viral genome. Consistent with our previous results (Sparks-
Thissen et al., 2004), gHV68.OVA-infected mice had 15-
fold fewer reactivating (Fig. 1A, P = 0.015) and 40-fold
fewer genome positive cells (Fig. 1B, P < 0.0001) than
gHV68.LacZ infected mice after treatment with the isotype
control antibody, demonstrating that the control antibody
does not alter the ability of antigen-specific CD4 T cells to
limit latent infection. In contrast, DO.11.10 mice treated
with anti-IFNg had equivalent frequencies of reactivating
and genome positive cells regardless of whether the
challenge virus expressed OVA (Fig. 1). Thus, the CD4 T
cell-dependent decrease in gHV68.OVA latency was com-
pletely eliminated by treatment with anti-IFNg. These data
indicate that IFNg plays an important role in limiting the
extent of latent infection by virus-specific CD4 T cells.
CD8 T cell and B cell-independent control of cHV68
replication and virulence by CD4 T cells requires IFNc
We next asked whether IFNg was necessary for helper
function-independent inhibition of gHV68 replication and
virulence by CD4 T cells (Sparks-Thissen et al., 2004). We
infected DO.11.10 RAG mice, which contain only OVA-
specific CD4 T cells and no other antigen-specific lympho-
cytes, with either gHV68.OVA or gHV68.LacZ. The mice
Fig. 1. CD4 T cell-mediated inhibition of the establishment of gHV68 latency requires IFNg. DO.11.10 mice were treated with either anti-IFNg or isotype
control antibodies. g = antibody prior to infection with gHV68.OVA or gHV68.LacZ. 16 days post-infection, peritoneal cells were harvested and subjected to
either limiting dilution ex vivo reactivation (A) or limiting dilution PCR assays (B). Data were pooled from four independent experiments.
Rapid Communication 203were depleted of IFNg (as before) beginning 1 day prior to
infection and then followed for survival. Consistent with our
previous data (Sparks-Thissen et al., 2004), DO.11.10 RAG
mice infected with gHV68.OVA and treated with the isotype
control antibody survived approximately 10 days longer thanFig. 2. Helper function-independent control of gHV68 virulence by CD4 T cells r
(C, D) animals were infected with either gHV68.OVA (A, C) or gHV68.LacZ (B
either anti-IFNg or isotype control antibody prior to infection. Numbers of animals
control: 10, (C) OTII RAG: 17, OTII RAG IFNg/: 10, (D) OTII RAG: 8, OTII
(A) anti-IFNg vs. isotype: P < 0.0001 and (C) OTII RAG vs. OTII RAG IFNg:mice infected with gHV68.LacZ (P = 0.0112, Figs. 2A and
B). In contrast, treatment of gHV68.OVA-infected DO.11.10
RAGmicewith IFNg-depleting antibody reduced survival by
approximately 10 days (P < 0.0001, Fig. 2A). We noted that
the IFNg-depleting antibody had no effect on the survival ofequires IFNg. DO.11.10 RAG (A, B), OTII RAG, or OTII RAG IFNg/
, D) and followed for survival. DO.11.10 RAG animals were treated with
per group: (A) anti-IFNg: 14, isotype control: 10, (B) anti-IFNg: 13, isotype
RAG IFNg/: 7. The following differences were statistically significant:
P = 0.0014. Data were pooled from 2 to 3 independent experiments.
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demonstrated that IFNg is not required for control of
infection of a challenge virus that does not express antigen
recognized by T cells (e.g., IFNg from NK cells). These data
demonstrate that IFNg is necessary for CD4 T cell-depend-
ent, helper-function-independent protection from lethal
infection.
To confirm these results with a wholly genetic approach,
we bred OTII RAG IFNg/ mice, where the only antigen-
specific lymphocytes are OVA-specific CD4 T cells that
lack IFNg expression. The OTII and DO.11.10 TCRs are
specific for the same MHC Class II epitope of OVA, though
OTII CD4 T cells are I-Ab restricted while DO.11.10 CD4 T
cells are I-Ad restricted (Barnden et al., 1998). And like
DO.11.10 CD4 T cells, OTII CD4 T cells (e.g., in OTII/
RAG/ mice) prolong survival of infection by
gHV68.OVA compared to gHV68.LacZ (Sparks-Thissen
et al., 2004) and (Figs. 2C and D). We then tested if the
protective effect seen in OTII CD4 T cells was lost in OTII
RAG IFNg/ mice. gHV68.OVA infected OTII RAG
IFNg/ mice succumbed to infection an average of 12
days sooner than gHV68.OVA infected OTII RAG mice
(Fig. 2C, P = 0.0010). In contrast, OTII RAG IFNg/
mice infected with gHV68.LacZ had similar survival
compared to OTII RAG mice infected with gHV68.LacZ
(Fig. 2D, P = 0.1874). Together, these data demonstrated
that CD4 T cell-mediated control of lethal infection is
dependent on IFNg. Furthermore, these data showed that
NK cell derived IFNg, which should be present regardless
of the level of T cell activation by cognate antigen, plays
little role in control of gHV68 infection in this experimental
system.
We next asked whether the lack of prolonged survival of
anti-IFNg treated gHV68.OVA infected DO.11.10 RAG
mice was associated with increased viral replication. Mice
were treated with anti-IFNg or the isotype control antibody
and then infected with gHV68.OVA or gHV68.LacZ.Fig. 3. Helper function-independent control of gHV68 replication by CD4 T cells
isotype control antibodies. g = antibody prior to infection with gHV68.OVA or gHV
harvested and the amount of virus present was quantitated by plaque assay. In eachSixteen days later, spleen, liver, and lung were harvested
and assayed for viral titer by plaque assay. Consistent with
the lethality data, DO.11.10 RAG mice infected with
gHV68.LacZ had high titers of virus in spleen, liver, and
lung after infection (Fig. 3). Treatment with anti-IFNg did
not alter these titers significantly (Fig. 3). On the other hand,
DO.11.10 RAG mice treated with the isotype control
antibody and infected with gHV68.OVA had a more than
3-log decrease in viral titer (compared to gHV68.LacZ) in
the spleen (Fig. 3A, P = 0.0037), liver (Fig. 3B, P =
0.0140), and lung (Fig. 3C, P = 0.0012). In contrast,
gHV68.OVA-infected DO.11.10 RAG mice treated with
IFNg-depleting antibody had equivalently high viral titers as
gHV68.LacZ-infected DO.11.10 RAG mice, demonstrating
that IFNg was required for CD4 T cell-dependent control of
gHV68 replication in multiple organs.
TH1 differentiated CD4 T cells are sufficient for control of
cHV68 infection
The previous experiments demonstrated that IFNg is
necessary for CD4 T cell-mediated control of gHV68
infection, as measured both by the capacity of CD4 T cells
to inhibit the establishment of latent infection and to control
acute replication and viral virulence. We next wanted to test
whether CD4 T cells that expressed IFNg were sufficient to
control infection. We therefore tested the effects of adoptive
transfer of the stable TH1 clone 3F6 derived from DO.11.10
mice that is specific for OVA (Wang et al., 1993). 3F6
expresses high levels of IFNg in response to OVA peptide
stimulation (Wang et al., 1993). We injected 1  106 3F6
cells into RAG mice and 2 days later infected the mice with
either gHV68.OVA or gHV68.LacZ. Viral titer was then
assayed 16 days after infection. gHV68.OVA-infected mice
which received 3F6 T cells had 80-fold less virus in the
spleen (Fig. 4A, P = 0.0053) and liver (Fig. 4B, P = 0.0144)
and 30-fold less virus in the lung (Fig. 4C, P = 0.0188) thanrequires IFNg. DO.11.10 RAG mice were treated with either anti-IFNg or
68.LacZ. Sixteen days after infection, spleen (A), liver (B), and lung (C) were
, groups of 8–10 mice were analyzed from two independent experiments.
Fig. 4. Adoptive transfer of a TH1 clone expressing IFNg is sufficient for control of gHV68 replication in RAG mice. 1  106 3f6 T cells (a TH1 differentiated
DO.11.10 clone) were transferred into RAG mice prior to infection with either gHV68.OVA or gHV68.LacZ. 16 days post-infection, mice were harvested and
spleen (A), liver (B), and lung (C) samples were analyzed by plaque assay. 12–13 mice were analyzed in each group in three independent experiments.
Rapid Communication 205mice infected with gHV68.LacZ. Thus, a stable T cell clone
with a TH1 phenotype can effectively control gHV68
infection.Summary
Previously, we demonstrated that CD4 T cells can inhibit
the establishment of gHV68 latency and can act in a helper-
independent fashion to limit gHV68 infection. In this study,
we show that IFNg is required for both of these activities of
CD4 T cells. Depletion of IFNg either genetically (in OTII
RAG IFNg/ mice) or using depleting antibodies (in
DO.11.10 RAG mice) demonstrated that IFNg is necessary
for CD4 T cell-mediated control of infection. In addition, we
show that IFNg producing TH1 CD4 T cells are sufficient
for control of infection. These data provide a reasonable
explanation for the similarities in phenotypes between
IFNg/ and MHC Class II/ mice (Cardin et al.,
1996; Dal Canto et al., 2001; Weck et al., 1997). Both of
these mice exhibit prolonged persistent replication in many
sites and develop severe arteritis.
It is important to note that TCR transgenic mice on a
RAG/ background eventually succumb to infection even
when the infecting virus expresses cognate antigen recog-
nized by TCR transgenic T cells. These data show that
neither CD4 T cells alone nor IFNg are sufficient to prevent
lethal gHV68 infection. The reason that CD4 T cells fail to
control gHV68 in the long term despite effectively limiting
gHV68 replication earlier during infection is not known. It
may be that long term control of productive infection
requires helper functions of CD4 T cells and therefore the
presence of B cells and/or CD8 T cells. Alternatively, viral
mutants that are no longer recognized by the TCR trans-
genic T cells may arise.
While our data do not directly address the source of
IFNg, two pieces of data suggest that CD4 T cell-derived
IFNg is important for control of gHV68 infection. First, the
capacity of a stably TH1 differentiated DO.11.10 T cell
clone expressing IFNg (Wang et al., 1993) to control
gHV68.OVA infection suggests that IFNg made by CD4 Tcell plays a role in control of gHV68 infection. Second,
IFNg has a minimal role in control of gHV68 replication or
lethal infection in the absence of viral expression of cognate
antigen for CD4 T cells present in the mice. If NK cell
derived IFNg were playing a major role in our model
system, neutralization of IFNg or deletion of the IFNg gene
should have altered infection with gHV68.LacZ; neither
treatment did. This conclusion rests on the reasonable
assumption that antigen-specific activation of CD4 T cells is
not required for NK cell secretion of IFNg.
The importance of IFNg, as shown by depletion or
genetic ablation, combined with the ability of a TH1
differentiated CD4 T cell clone to control lytic infection
suggests that TH1 differentiated CD4 T cells may be
important for control of gHV68 infection. This is consistent
with CD4 T cells identified in response to EBV antigens
where many of the T cells express IFNg best not IL4
(Bickham et al., 2001; Herr et al., 2000; Leen et al., 2001;
Omiya et al., 2002; Munz et al., 2000; Wilson and Morgan,
2002). One hypothesis for the mechanism of IFNg action in
CD4 T cell-dependent control of gHV68 infection is that
IFNg acts directly on gHV68 infected cells to control
replication. This is supported by two observations. First,
bone marrow transplantation studies show that expression of
the IFNg receptor on somatic cells is required for control of
persistent gHV68 replication in the aorta (Dal Canto et al.,
2001). Second, IFNg treatment of primary smooth muscle
and endothelial cells significantly inhibits gHV68 replication
(Dal Canto et al., 2001). However, the specific mechanism(s)
by which IFNg acts against gHV68 are not known. It will be
important to determine whether IFNg acts directly on
infected cells or via immunomodulatory effects, or both.Materials and methods
Mice
Mice were housed and bred under specific-pathogen-free
conditions at the Washington University School of Medicine
in accordance with all federal and university guidelines.
Rapid Communication206DO.11.10 RAG and OTII RAG mice were bred in our
facility as previously described (Sparks-Thissen et al.,
2004). OTII RAG IFNg/ mice were generated by first
breeding RAG IFNg/ mice and then crossing these mice
with OTII RAG mice. Mice were genotyped by FACS for
peripheral blood TCR transgenic CD4 T cells and by PCR
for the IFNg/ mutation. For all experiments, mice were
at least 8 weeks of age and were age- and sex-matched
within experiments.
Viruses and viral assays
gHV68.v-cyclin.LacZ and gHV68.v-cyclin.OVA [(Bra-
aten et al., 2005; Van Dyk et al., 2000) herein referred to as
gHV68.LacZ and gHV68.OVA, respectively] were pas-
saged in NIH3T12 fibroblasts (Tibbetts et al., 2003a). Mice
were infected with 100 plaque forming units (pfu) of virus
by intraperitoneal infection (Tibbetts et al., 2003a). Viral
titers were determined by plaque assay (Tibbetts et al.,
2003a,b). Briefly, harvested organs were frozen in 1 ml of
media, thawed, and then homogenized with 100 Al of 1.0
mm zirconia/silica beads (Biospec, Inc.) at 3200 rpm for 2
min with a Mini-Bead-Beater-8 (Biospec Inc.) prior to
plaque assay. All titers were determined in parallel with a
viral stock of known titer. The limit of detection of the assay
used is 50 pfu per organ.
Quantitation of latency and persistent replication
The frequency of cells reactivating from latency and the
level of persistent viral replication were determined as
described (Tibbetts et al., 2002, 2003a,b). Briefly, cells were
pooled from 4 to 5 mice per group and then plated in serial
2-fold dilutions (24 wells per dilution) starting at 105 cells/
well for splenocytes and 4  104 cells/well for peritoneal
cells onto an indicator monolayer of mouse embryo
fibroblasts (MEFs) in 96-well plates. Reactivation was
detected as CPE in the MEF monolayers over 21 days of
culture. To detect preformed infectious virus (persistent
replication) parallel samples were mechanically disrupted
prior to plating. This procedure kills > 99% of the cells but
has at most a 2-fold effect on viral titer, allowing for
distinction between reactivation from latency (which
requires live cells) and persistent viral replication. To
determine the frequency of cells carrying the viral genome,
single-copy sensitive nested PCR assays for the gHV68
gene50 were performed on serial dilutions of cells as
previously described (Tibbetts et al., 2002). Briefly, cells
were serially diluted 3-fold starting at 104 cells per reaction
in a background of uninfected 3T12 cells such that a total of
104 cells were present in each sample. Single copies of a
plasmid containing gene 50 in a background of 3T12 cells
were in included as positive controls. 3T12 samples with no
plasmid were included as a negative control. After over-
night lysis of cells in proteinase K, nested PCR was
performed and products were visualized on a 1.5% agarosegel. For the experiments reported here, all assays demon-
strated approximately single-copy sensitivity, with no false
positives.
Depletion of IFNc in vivo
H22 [anti-IFNg, (Bancroft et al., 1987; Schreiber et al.,
1985)] and PIP [isotype control, (Mandik-Nayak et al.,
2001)] were grown in HyQ ADCF-Ab medium (Hyclone) in
INTEGRA CL1000 flasks (INTEGRA Biosciences, Ltd.).
One milligram of antibody was injected i.p. the day prior to
infection. 500 Ag of antibody was then injected every 7 days
for the duration of the experiment.
T cell transfer experiments
The OVA-specific TH1 clone, 3F6, was grown as
previously described (Wang et al., 1993). 1  106 cells
were injected i.p. 2 days prior to infection with
gHV68.OVA or gHV68.LacZ. Prior to infection, greater
than 90% of the cells injected were shown to produce IFNg
as shown by intracellular FACS (data not shown).
Statistical methods
All data were analyzed with GraphPad Prism software
(GraphPad Software, San Diego, CA). Frequencies of
reactivating and genome positive cells were calculated on
the basis of the Poisson distribution by determining the cell
number at which 63.2% of the wells scored positive. The
frequency of cells containing preformed virus were calcu-
lated as previously described (Tibbetts et al., 2003a). The
frequencies of reactivating cells and genome positive cells
were compared by paired t test. Mice were scored as dead at
the time of death or when sacrificed if moribund, and
survival data were analyzed by the Mantel–Haenzsel test.
Acute titer data were analyzed using the Mann–Whitney U
test. All error bars represent the SEM.Acknowledgments
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